Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
1.33 (1y: -91%)
Market Cap 53.6 M P/E(ttm)
Enterprise Value 7.79 M P/B 5.80
AFFY- NAS (USA)
Affymax, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$1.33
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry		 vs
history
Cash to Debt 8.818
AFFY's Cash to Debt is ranked lower than
59% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AFFY: 8.818 )
AFFY' s 10-Year Cash to Debt Range
Min: 8.82   Max: 13531.3
Current: 8.82
8.82
13531.3
Equity to Asset 0.07
AFFY's Equity to Asset is ranked lower than
54% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.54 vs. AFFY: 0.07 )
AFFY' s 10-Year Equity to Asset Range
Min: -3.14   Max: 0.64
Current: 0.07
-3.14
0.64
F-Score: 2
Z-Score: -18.93
M-Score: -15.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry		 vs
history
Operating margin (%) -97.50
AFFY's Operating margin (%) is ranked lower than
59% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -52.55 vs. AFFY: -97.50 )
AFFY' s 10-Year Operating margin (%) Range
Min: -45958.1   Max: -12.8
Current: -97.5
-45958.1
-12.8
Net-margin (%) -99
AFFY's Net-margin (%) is ranked lower than
60% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -55.70 vs. AFFY: -99 )
AFFY' s 10-Year Net-margin (%) Range
Min: -44021.6   Max: -12.5
Current: -99
-44021.6
-12.5
ROE (%) -1128
AFFY's ROE (%) is ranked lower than
72% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -16.60 vs. AFFY: -1128 )
AFFY' s 10-Year ROE (%) Range
Min: -1128   Max: -19.4
Current: -1128
-1128
-19.4
ROA (%) -79
AFFY's ROA (%) is ranked lower than
76% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -14.40 vs. AFFY: -79 )
AFFY' s 10-Year ROA (%) Range
Min: -79   Max: -10.7
Current: -79
-79
-10.7
Revenue Growth (%) -19.2
AFFY's Revenue Growth (%) is ranked higher than
56% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. AFFY: -19.2 )
AFFY' s 10-Year Revenue Growth (%) Range
Min: -28.4   Max: 120.5
Current: -19.2
-28.4
120.5
EBITDA Growth (%) -11.6
AFFY's EBITDA Growth (%) is ranked higher than
64% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -11.35 vs. AFFY: -11.6 )
AFFY' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -1
Current: -11.6
EPS Growth (%) -10.8
AFFY's EPS Growth (%) is ranked higher than
61% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. AFFY: -10.8 )
AFFY' s 10-Year EPS Growth (%) Range
Min: -55   Max: -1
Current: -10.8
-55
-1
ยป AFFY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

AFFY Guru Trades in Q2 2012

Steven Cohen 1,000 sh (New)
» More
Q3 2012

AFFY Guru Trades in Q3 2012

Jim Simons 158,100 sh (New)
Steven Cohen Sold Out
» More
Q4 2012

AFFY Guru Trades in Q4 2012

Steven Cohen 16,205 sh (New)
Jim Simons Sold Out
» More
Q1 2013

AFFY Guru Trades in Q1 2013

Paul Tudor Jones 305,400 sh (New)
Jim Simons 1,027,867 sh (New)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AFFY

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2012-03-31 Sold Out 0.06%$6.53 - $14.31 $ 1.27-86%0
George Soros 2011-12-31 Add 800.9%0.05%$4.24 - $7.8 $ 1.27-76%200000
George Soros 2011-09-30 Reduce -83.4%0.01%$4.04 - $7.78 $ 1.27-77%22200
George Soros 2011-06-30 New Buy0.01%$5.85 - $7.16 $ 1.27-81%133717
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/B 5.50
AFFY's P/B is ranked lower than
74% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. AFFY: 5.50 )
AFFY' s 10-Year P/B Range
Min: 0.89   Max: 106.59
Current: 5.5
0.89
106.59
P/S 1.46
AFFY's P/S is ranked lower than
53% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 6.90 vs. AFFY: 1.46 )
AFFY' s 10-Year P/S Range
Min: 0.8   Max: 11.68
Current: 1.46
0.8
11.68

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 3.6
AFFY's Price/Net Current Asset Value is ranked higher than
84% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 32.60 vs. AFFY: 3.6 )
AFFY' s 10-Year Price/Net Current Asset Value Range
Min: 0.8   Max: 110.8
Current: 3.6
0.8
110.8
Price/Tangible Book 5.5
AFFY's Price/Tangible Book is ranked higher than
88% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. AFFY: 5.5 )
AFFY' s 10-Year Price/Tangible Book Range
Min: 0.4   Max: 82.6
Current: 5.5
0.4
82.6
Price/Median PS Value 0.4
AFFY's Price/Median PS Value is ranked higher than
92% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. AFFY: 0.4 )
AFFY' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 2
Current: 0.4
0.4
2
Earnings Yield (Greenblatt) 5354.20
AFFY's Earnings Yield (Greenblatt) is ranked lower than
95% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. AFFY: 5354.20 )
AFFY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 5396.7
Current: 5354.2
0
5396.7
Forward Rate of Return (Yacktman) -216.82
AFFY's Forward Rate of Return (Yacktman) is ranked higher than
60% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -4.65 vs. AFFY: -216.82 )
AFFY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -216.82

Business Description

Affymax, Inc. is a Delaware corporation, was incorporated on July 20, 2001. It is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. It operates in one business segment, which encompasses all the geographical regions. It completed Phase 3 clinical trials of its product candidate, peginesatide, to treat anemia associated with chronic kidney disease in early 2010. In May 2011, it submitted its New Drug Application, or NDA, to the United States, or U.S., Food and Drug Administration, or FDA, seeking approval for peginesatide to treat adult dialysis patients with anemia associated with chronic kidney disease. Its NDA is currently under review with the FDA, with an action date of March 27, 2012 under the Prescription Drug User Fee Act. In December 2011, the FDA Oncologic Drugs Advisory Committee, or ODAC, voted 15 to 1, with 1 abstention, that peginesatide demonstrated a favorable benefit/risk profile for use in the treatment of dialysis patients with anemia due to chronic kidney disease. Peginesatide is chemically synthesized and peptide-based. Final peginesatide drug product is currently manufactured as a buffered aqueous solution for intravenous or subcutaneous administration. All of its current good manufacturing practices, or GMP, manufacturing is outsourced to third parties with oversight by its internal managers. It has limited non-GMP manufacturing capacity in-house. It has established long term commercial supply agreements with two contract manufacturers, or CMOs, for peginesatide active pharmaceutical product, or API. Under its worldwide collaboration with Takeda, it will be responsible, through its CMOs, for the manufacture and supply of all quantities of peginesatide API to be used in development and commercialization worldwide, and Takeda will be responsible for final drug product manufacture and control. The Company faces competition from many different sources, including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies and private and public research institutions. The clinical development, manufacturing and potential marketing of peginesatide is subject to regulation by various authorities in the U.S., the E.U. and other countries, including, in the U.S., the FDA, and, in the E.U., the EMA. In the U.S., pharmaceutical products are subject to extensive regulation by the FDA.
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:A5Y.Germany
ยป More Articles for AFFY

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: PII, ASNA, FIO, VVUS, AFFY Jul 23 2012 
AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 52,896 Shares May 19 2010 
AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 180,410 Shares May 13 2010 
AFFYMAX, INC. (AFFY) EVP, Corp. Development and CFO Paul B Cleveland sells 55,935 Shares Feb 26 2010 
AFFYMAX, INC. (AFFY) President and CEO Arlene Morris sells 101,100 Shares Sep 30 2009 
AFFYMAX, INC. (AFFY) President and CEO Arlene Morris sells 6,555 Shares Sep 02 2009 
AFFYMAX, INC. Reports Operating Results (10-Q) Aug 05 2009 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial